

Full Portfolio Holdings* as of January 31, 2024

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			1,399,970	1,399,970	1.01%
COMMON STOCKS					
Eli Lilly & Co.			20,975	13,541,670	9.79%
UnitedHealth Group, Inc.			19,908	10,187,720	7.37%
Merck & Co., Inc.			72,479	8,754,014	6.33%
Danaher Corp.			22,293	5,348,314	3.87%
Stryker Corp.			11,742	3,939,206	2.85%
Boston Scientific Corp.			61,249	3,874,612	2.80%
Vertex Pharmaceuticals, Inc.			8,529	3,696,298	2.67%
HCA Healthcare, Inc.			11,672	3,558,793	2.57%
Thermo Fisher Scientific, Inc.			6,380	3,438,692	2.49%
Centene Corp.			42,417	3,194,424	2.31%
Zoetis, Inc.			16,547	3,107,692	2.25%
Cencora, Inc.			12,851	2,990,171	2.16%
Abbott Laboratories			26,016	2,943,710	2.13%
AstraZeneca PLC			37,931	2,527,722	1.83%
AbbVie, Inc.			14,990	2,464,356	1.78%
Humana, Inc.			6,241	2,359,472	1.71%
Edwards Lifesciences Corp.			29,772	2,336,209	1.69%
Dexcom, Inc.			18,337	2,225,195	1.61%
Agilent Technologies, Inc.			15,552	2,023,315	1.46%
Molina Healthcare, Inc.			5,675	2,022,797	1.46%
Pfizer, Inc.			74,247	2,010,609	1.45%
Regeneron Pharmaceuticals, Inc.			2,082	1,962,868	1.42%
Daiichi Sankyo Co. Ltd.			61,335	1,836,311	1.33%
ICON PLC			5,962	1,555,307	1.12%
Biogen, Inc.			6,094	1,503,146	1.09%
Shockwave Medical, Inc.			6,249	1,413,836	1.02%
Laboratory Corp. of America Holdings			6,327	1,406,492	1.02%
Illumina, Inc.			9,077	1,298,102	0.94%
Acadia Healthcare Co., Inc.			15,671	1,287,216	0.93%
Encompass Health Corp.			16,482	1,170,881	0.85%
Insulet Corp.			6,005	1,146,174	0.83%
Hologic, Inc.			14,830	1,103,945	0.80%
Novartis AG			10,149	1,049,546	0.76%
Argenx SE			2,737	1,041,456	0.75%
Eisai Co. Ltd.			21,409	1,008,120	0.73%
Waters Corp.			3,069	975,052	0.71%
Chugai Pharmaceutical Co. Ltd.			26,700	960,405	0.69%
Option Care Health, Inc.			30,260	945,322	0.68%
Repligen Corp.			4,780	905,332	0.65%
GSK PLC			41,495	820,677	0.59%

Full Portfolio Holdings* as of January 31, 2024

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Alnylam Pharmaceuticals, Inc.			4,612	797,461	0.58%
United Therapeutics Corp.			3,671	788,457	0.57%
Evolent Health, Inc.			25,685	755,396	0.55%
Teleflex, Inc.			3,097	752,045	0.54%
Qiagen NV			17,193	750,657	0.54%
Cytokinetics, Inc.			9,385	733,250	0.53%
Gilead Sciences, Inc.			9,340	730,948	0.53%
Surgery Partners, Inc.			23,351	716,642	0.52%
Otsuka Holdings Co. Ltd.			18,000	707,550	0.51%
Elanco Animal Health, Inc.			47,784	704,336	0.51%
UCB SA			7,416	697,591	0.50%
Addus HomeCare Corp.			7,844	679,290	0.49%
Apellis Pharmaceuticals, Inc.			10,437	660,558	0.48%
Immunocore Holdings PLC			9,022	652,200	0.47%
Exact Sciences Corp.			9,600	627,840	0.45%
Ascendis Pharma AS			4,384	569,613	0.41%
Revolution Medicines, Inc.			20,265	562,354	0.41%
Privia Health Group, Inc.			27,760	559,642	0.40%
Structure Therapeutics, Inc.			12,590	549,176	0.40%
Inari Medical, Inc.			9,406	535,672	0.39%
Sarepta Therapeutics, Inc.			4,423	526,293	0.38%
agilon health, Inc.			87,052	512,736	0.37%
Vaxcyte, Inc.			7,165	511,724	0.37%
DiaSorin SpA			5,517	507,338	0.37%
Tecan Group AG			1,320	503,863	0.36%
Celldex Therapeutics, Inc.			13,996	492,939	0.36%
Crinetics Pharmaceuticals, Inc.			13,080	477,158	0.35%
Veracyte, Inc.			19,054	476,731	0.34%
Genmab AS			1,719	475,341	0.34%
Merus NV			13,255	472,938	0.34%
Bio-Techne Corp.			6,596	463,831	0.34%
Alkermes PLC			16,779	453,872	0.33%
Rocket Pharmaceuticals, Inc.			15,435	443,448	0.32%
Verona Pharma PLC			23,993	440,272	0.32%
Becton Dickinson & Co.			1,839	439,172	0.32%
Xenon Pharmaceuticals, Inc.			9,645	436,147	0.32%
Moderna, Inc.			4,016	405,817	0.29%
Genus PLC			13,370	388,338	0.28%
Ultragenyx Pharmaceutical, Inc.			8,796	387,992	0.28%
Syndax Pharmaceuticals, Inc.			17,995	368,718	0.27%
Blueprint Medicines Corp.			4,492	357,249	0.26%
Immatics NV			31,380	356,477	0.26%
Bridgebio Pharma, Inc.			10,370	355,587	0.26%
Legend Biotech Corp.			5,488	302,169	0.22%
QuidelOrtho Corp.			4,382	300,211	0.22%

Full Portfolio Holdings* as of January 31, 2024

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Longboard Pharmaceuticals, Inc.			12,650	268,686	0.19%
Zai Lab Ltd.			11,858	255,777	0.18%
Hapvida Participacoes e Investimentos SA			321,235	251,573	0.18%
Morphic Holding, Inc.			7,767	246,136	0.18%
Inspire Medical Systems, Inc.			1,165	245,664	0.18%
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.			23,400	239,734	0.17%
PTC Therapeutics, Inc.			8,823	230,192	0.17%
Sage Therapeutics, Inc.			7,914	202,915	0.15%
Prothena Corp. PLC			5,956	169,091	0.12%
Guardant Health, Inc.			7,117	156,076	0.11%
Smith & Nephew PLC			7,285	101,881	0.07%
Contra Abiomed, Inc.			885	903	0.00%
FOREIGN CURRENCY					
BRAZILIAN REAL			226,512	45,719	0.03%
SWISS FRANC			35	41	0.00%
EURO CURRENCY			19	21	0.00%
DANISH KRONE			34	5	0.00%
HONG KONG DOLLAR			5	0.58	0.00%
JAPANESE YEN			1	0.01	0.00%
POUND STERLING			(0.16)	(0.20)	0.00%
REPURCHASE AGREEMENTS					
FIXED, Inc. CLEARING CORP.REPO		2/1/2024	349,610	349,610	0.25%
TOTAL INVESTMENTS				138,486,211	100.14%
OTHER ASSETS LESS LIABILITIES				(186,996)	-0.14%
TOTAL NET ASSETS				138,299,215	100.00%

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22